Please note that this summary only contains information from the full scientific abstract: View ESMO Scientific Abstract
The study drugs sunitinib and pazopanib are both approved to treat people with advanced kidney cancer. Sunitinib, but not pazopanib, is approved to treat people at high risk of recurrent renal cell carcinoma after kidney surgery.
Researchers must look at the results of many types of studies to understand whether a study drug works, how it works, and whether it is safe to prescribe to patients.
This summary reports the results of only two studies. The results of this study might be different from the results of other studies that the researchers look at.
More information can be found in the scientific
abstract of this study, which you can access here:
View ESMO Scientific Abstract
235 East 42nd Street NY, NY 10017
Phone (United States): +1 212-733-2323
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080
The sponsors would like to thank all of the people who took part in these studies.